Photo Credit: ilbusca
The following is a summary of “Autologous Peripheral Blood-Derived Orthobiologics for the Management of Shoulder Disorders: A Review of Current Clinical Evidence,” published in the November 2024 issue of Pain by Gupta et al.
Shoulder pain is a common musculoskeletal disorder. While traditional treatments offer a temporary relief, autologous peripheral blood-derived orthobiologics (APBOs) like platelet-rich plasma (PRP) and platelet lysate (PL), autologous conditioned serum (ACS), gold-induced cytokine (GOLDIC), plasma rich in growth factors (PRGF), growth factor concentrate (GFC), autologous protein solution (APS), and hyperacute serum (HS) are being explored for the potential in managing shoulder disorders.
Researchers conducted a retrospective study to summarize the outcomes of clinical studies evaluating the use of APBOs in managing shoulder disorders.
They searched multiple databases (PubMed, Web of Science, Embase, and Scopus) using terms for APBOs and various shoulder disorders for English-language articles published up to September 11, 2024, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
The results showed that only 6 clinical studies met the pre-defined search and inclusion criteria. Among these, 1 study on PL, 2 studies on ACS, 2 on PRGF, and 1 on APS were included. No studies were identified on the use of GOLDIC, GFC, or HS.
Investigators concluded that PL, ACS, PRGF, and APS were safe and could improve pain and function in patients with shoulder disorders, although more high-quality studies were needed to establish efficacy and optimal use.
Source: link.springer.com/article/10.1007/s40122-024-00684-5
